Skip to main content

Pfizer enCompass Reimbursement Support and Patient Support

Pfizer

ClosedLink broken·Sep 13, 2026

The Pfizer enCompass Co-Pay Assistance Program helps commercially insured patients reduce their out-of-pocket costs for ABRILADA treatment, offering a co-pay as low as $0, with an annual maximum benefit ranging from $4,000 to $14,000. Additionally, eligible patients may receive a Sharps Container and Travel Kit. The program is not available for patients with state or federally funded insurance or cash-paying patients.

Enrollment cycle
rolling

Apply

Application goes directly to Pfizer. RxCopays does not receive compensation.

Go to application →

Status source

Automated check 2026-09-13T05:00:51.186Z: application_url + organization_url return 404/DNS-fail. Grant may have ended. Please submit a correction via /add-resource if this is incorrect.

Rare-disease support beyond financial help

This grant covers 12 rare conditions. For specialists, clinical trials, and patient communities, our sister site UniteRare.org has in-depth pages: